Blar i NTNU Open på forfatter "Lømo, Jon"

Viser treff 1-5 av 5

    • Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial 

      Røssevold, Andreas Hagen; Andresen, Nikolai Kragøe; Bjerre, Christina Annette; Gilje, Bjørnar; Jakobsen, Erik Hugger; Raj, Sunil Xavier; Falk, Ragnhild Sørum; Russnes, Hege Elisabeth Giercksky; Jahr, Thea; Ruud, Randi Margit; Lømo, Jon; Garred, Øystein; Chauhan, Sudhir Kumar; Lereim, Ragnhild Reehorst; Dunn, Claire; Naume, Bjørn; Kyte, Jon A (Peer reviewed; Journal article, 2022)
      Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast cancer (mTNBC) but only for PD-L1positive disease. The randomized, placebo-controlled ALICE trial (NCT03164993, 24 May 2017) evaluated ...

    • Dietary changes in early-stage breast cancer patients from pre-surgery and over the 12 months post-surgery 

      Brunvoll, Sonja Hjellegjerde; Thune, Inger; Bertheussen, Gro Falkener; Fjeldheim, Frøydis Nyborg; Flote, Vidar Gordon; Frydenberg, Hanne; Lundgren, Steinar; Skjerven, Helle; Lømo, Jon; Fagerland, Morten; McTiernan, Anne; Schlichting, Ellen; Hjartåker, Anette (Peer reviewed; Journal article, 2020)
      The time after a breast cancer diagnosis is a potential period for making positive dietary changes, but previous results are conflicting. The main aim of the present study was to study breast cancer patients’ dietary changes ...

    • Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer 

      Flote, Vidar Gordon; Vettukattil, Muhammad Riyas; Bathen, Tone Frost; Egeland, Thore; McTiernan, Anne; Frydenberg, Hanne; Husøy, Anders; Finstad, Sissi Espetvedt; Lømo, Jon; Garred, Øystein; Schlichting, Ellen; Wist, Erik; Thune, Inger (Journal article; Peer reviewed, 2016)
      Background: High-Density Lipoprotein (HDL)-cholesterol, has been associated with breast cancer development, but the association is under debate, and whether lipoprotein subfractions is associated with breast tumor ...

    • Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment 

      Madssen, Torfinn Støve; Thune, Inger; Flote, Vidar Gordon; Lundgren, Steinar; Bertheussen, Gro Falkener; Frydenberg, Hanne; Wist, Erik; Schlichting, Ellen; Schäfer, Hartmut; Fjøsne, Hans Erikssønn; Vettukattil, Muhammad Riyas; Lømo, Jon; Bathen, Tone Frost; Giskeødegård, Guro F. (Journal article; Peer reviewed, 2018)
      Background Breast cancer treatment has metabolic side effects, potentially affecting risk of cardiovascular disease (CVD) and recurrence. We aimed to compare alterations in serum metabolites and lipoproteins during treatment ...

    • Normal and unusual days for dietary intake during the 12 months after a breast cancer diagnosis in women 

      Brunvoll, Sonja Hjellegjerde; Flote, Vidar Gordon; Halset, Eline Holli; Bertheussen, Gro Falkener; Skjerven, Helle; Lømo, Jon; Thune, Inger; Hjartåker, Anette (Peer reviewed; Journal article, 2022)
      Purpose There are several reasons to report days as being unusual with regard to dietary intake, including special occasions and celebrations. For breast cancer patients during the 12 month post-surgery period, unusual ...